FOB Holdings Overseas News
Technology · Series “Binotec Technology” 1 of 20

Below the Skin's Outer Layer, Past the Gut's Absorption Barrier

How drug-delivery technology from a pharmaceutical research lab became cosmetic and food ingredients — Binotec's nano-delivery platforms, seen through three US patents

DAEGU, Korea — FOB Holdings Overseas News | September 22, 2026 | Published in seven languages

Skincare products built on Binotec's transdermal delivery technology. On the same Hydroethosome® platform, the company tunes particle size from 40 to 250 nanometers depending on the ingredient. (Photo: Binotec)
Skincare products built on Binotec's transdermal delivery technology. On the same Hydroethosome® platform, the company tunes particle size from 40 to 250 nanometers depending on the ingredient. (Photo: Binotec)

"Patented nano-delivery technology" has long been a routine line in cosmetic ingredient catalogs, and ingredient buyers' questions have become correspondingly specific: which patents, how small are the particles and how much do they carry, and has any of it been measured in human skin or human blood?

Binotec Co., Ltd. (CEO Yu-mi Kim), a nano drug-delivery technology company that opened a GMP plant in Gyeongsan, North Gyeongsang Province, last July, is one of the few companies able to answer all three on paper. This report draws on the company's English technical catalog, US and European patent records, a human clinical paper in an international journal, and finished-product test reports reviewed by our editorial team.

Origins in a pharmaceutical laboratory

Binotec's technology grew out of drug delivery systems (DDS) used in pharmaceuticals — packaging an active compound in a carrier so that it reaches its target before it is degraded or cleared. CEO Yu-mi Kim completed postdoctoral research at Georgia Tech in the US and in dentistry at Kyungpook National University before developing carriers as a principal researcher at CJ CheilJedang's pharmaceutical research institute; her work in the field spans 25 years. Founded in 2014 as Celize Cosmetic and renamed Binotec in 2018, the company chose to apply those principles to cosmetic actives and food ingredients.

The problem it addresses is simple to state. Skin has a tough outer layer, the stratum corneum, that blocks outside substances; the gut has an absorption barrier that keeps out compounds that do not dissolve well in water. However much of an ingredient is added to a formula, the amount that actually reaches the target layer often falls far short. Binotec addresses the two barriers with two distinct carrier families.

"The value of a delivery technology lies not in how much of an ingredient you put in, but in how precisely it arrives." — Yu-mi Kim, CEO, Binotec

Transdermal delivery: Hydroethosome® and five derivative carriers

Hydroethosome® encapsulates an active together with a hydrogel inside nano-scale lipid vesicles (ethosomes) and carries it into the skin. Patented in Korea in 2017 (KR 10-1810160), it was granted a US patent in September 2022 (US 11,452,679 B2) and has been filed in Thailand and Germany via PCT. The company credits the hydrogel with raising both the stability and the encapsulation rate of the ingredient.

Schematic of the Hydroethosome® vesicle and the Korean, US, Thai, German and PCT patent documents. Korean (2017) and US (2022) grants are complete; the Thai and German filings are pending. (Source: Binotec 6G REPOVE technical catalog)
Schematic of the Hydroethosome® vesicle and the Korean, US, Thai, German and PCT patent documents. Korean (2017) and US (2022) grants are complete; the Thai and German filings are pending. (Source: Binotec 6G REPOVE technical catalog)

Several derivative carriers have been built on the platform, each designed for the ingredient it carries. The specifications published in the company's 2024 English technical catalog are as follows.

CarrierPayloadParticle size · encapsulationEvidence · IP
HydroDNA™Salmon-derived PDRN (Sodium DNA)≈ 40 nm · >90% encapsulatedKR 10-2678046 · Franz-cell skin absorption test
Hyalutosome™Low-molecular-weight hyaluronic acid≈ 40 nmKR application 10-2021-0191800 · Franz-cell test
Triaction peptosome®Three peptides≈ 160 nmHydroethosome® platform
Multisome® LicoriceLicorice root extract (glycyrrhizic acid)≈ 120 nmCo-encapsulation of multiple actives
Hydropartisome®Copper tripeptide and other scalp actives200–250 nm solid lipid nanoparticles; follicular route, sustained releaseKR 10-2037354 · 10-2190935 · US 11,826,474 B2

Two points deserve a buyer's attention. First, PDRN — a DNA fragment whose negative charge makes it notoriously difficult to hold stably in lipid vesicles — is encapsulated at about 40 nm with better than 90% efficiency. Second, particle size on the same platform is deliberately varied from 40 nm for hyaluronic acid to 250 nm for follicle-targeted solid lipid particles, according to where the active needs to go.

Franz-cell fluorescence images of HydroDNA™ skin absorption before application and at 5 minutes, 20 minutes and 1 hour. In-house test data. (Source: Binotec)
Franz-cell fluorescence images of HydroDNA™ skin absorption before application and at 5 minutes, 20 minutes and 1 hour. In-house test data. (Source: Binotec)

Skin penetration was documented in-house by Franz-cell testing, and at finished-product level by third-party testing: for REPOVE Solution B, the Korea Institute of Dermatological Sciences measured a 150% increase in skin absorption rate, and 223% increases in absorption speed and depth, 30 minutes after application.

Release pattern of the sixth-generation carriers. According to the company, particle size and structure determine whether an active is released in the epidermis, the dermis or the hair follicle. (Source: Binotec 6G REPOVE technical catalog)
Release pattern of the sixth-generation carriers. According to the company, particle size and structure determine whether an active is released in the epidermis, the dermis or the hair follicle. (Source: Binotec 6G REPOVE technical catalog)

Oral delivery: Absosome™, and numbers measured in people

For ingredients taken by mouth, Absosome™ coats nano-lipid particles with multiple layers of materials such as chitosan and polyglutamic acid, shielding the payload through gastric acid and digestion and assisting uptake in the intestine. This multi-coated nanoparticle technology was granted a US patent in 2025 (US 12,318,462 B2) and a European patent (EP 3995126), validated in Germany, the United Kingdom and France.

Oral-delivery claims are frequently supported only by animal data. Binotec has published the results of a human pharmacokinetic study in an international journal. At the Efficacy Evaluation Center of Jeonbuk National University Hospital, 20 healthy adult men were divided into two groups: one took 400 mg of HYDROCUMIN™, curcumin encapsulated in Absosome™; the other took 2,000 mg of conventional curcumin. Peak blood concentration (Cmax) was 445.15 versus 38.30, and total blood exposure (AUC) 2,477 versus 561. Even at one-fifth the dose, AUC was 4.4 times higher — about 23 times higher on an equal-dose basis. The results were published in Scientific Reports in 2026. An earlier animal study reported a 109-fold AUC difference; that result is preclinical.

HYDROCUMIN™ sticks, Binotec's curcumin ingredient built on Absosome™ oral delivery, and the structure of its nano carrier. The company draws a clear line between the absorption metrics confirmed in its human pharmacokinetic study and any health effect. (Photo: Binotec)
HYDROCUMIN™ sticks, Binotec's curcumin ingredient built on Absosome™ oral delivery, and the structure of its nano carrier. The company draws a clear line between the absorption metrics confirmed in its human pharmacokinetic study and any health effect. (Photo: Binotec)

The company is explicit that these are absorption metrics and do not imply any specific health effect. What an overseas buyer can review alongside the ingredient specification is human data with a named institution, subject numbers, doses and endpoints on the record.

Reading the patent portfolio

JurisdictionNumberSubjectStatus
United StatesUS 11,452,679 B2Hydroethosome® transdermal carrierGranted 27 Sep 2022
United StatesUS 11,826,474 B2Nano-lipid carrier (Hydropartisome® family)Granted
United StatesUS 12,318,462 B2Multi-coated nanoparticles (Absosome™ family)Granted 2025
EuropeEP 3995126Multi-coated nanoparticlesGranted · validated DE / GB / FR
Korea18 patentsCarrier, fermentation and extraction technologiesGranted
InternationalPCT/KR2018/002808 · TH 1901001249 · DE 11 2018 003 377.5Hydroethosome® filingsPending

Nano-carriers are not a new idea; the field has developed continuously since liposomes were first described in the 1960s. What Binotec offers as its point of difference is the integration of carrier, fermentation and extraction technologies within one company, linking ingredient development to finished-product manufacture, with the work documented in patents and ten published papers — from a 2019 ethosome transdermal study in the Journal of Drug Delivery Science and Technology to the 2026 human study.

Three routes open to buyers

Binotec's GMP plant in Gyeongsan, opened in July. The plant issues a test report for every finished-product batch, covering appearance, pH, viscosity, microbial limits and active content. (Photo: Binotec)
Binotec's GMP plant in Gyeongsan, opened in July. The plant issues a test report for every finished-product batch, covering appearance, pH, viscosity, microbial limits and active content. (Photo: Binotec)

Binotec currently has 19 cosmetic ingredients and five food ingredients, and the carriers described above were first used in its own skincare brand REPOVE and inner-beauty brand ABSOVE. Three forms of collaboration are open to overseas brands: supply of encapsulated ingredients; joint development in which a partner's own active is encapsulated in a Binotec carrier; and OEM/ODM manufacture at the Gyeongsan plant, which has production history for EU CPNP-notified and MUI Halal-certified products.

"On the strength of technology that can be verified through patents and published papers, we intend to broaden ingredient supply, joint development and manufacturing partnerships with overseas brands," Kim said.

This series introduces Binotec's technologies and products one at a time, in seven languages. The next article follows the Hydroethosome® platform through its sixth generation and the development of HydroDNA™.

About Binotec

Binotec Co., Ltd. is a Daegu-based bio company applying nano-delivery science to cosmetic and food ingredients. Its platforms include the transdermal carrier Hydroethosome®, the oral carrier Absosome™, the fermentation platform Absobiome™ and the high-concentration extraction technology Absotraction™, and the company holds 18 Korean patents, three US patents and one European patent. Binotec was named to Korea's "Innovative Companies 1000" by the Ministry of Science and ICT and received the Minister of SMEs and Startups Award for venture promotion in 2024. It opened a GMP plant in Gyeongsan in July 2026, was an official sponsor of APEC 2025, and exhibited at CES 2026 and Cosmoprof Bologna 2026. binotec.co.kr

Media contact

Media Division, FOB Holdings · aninyoul@fobholdings.co.kr · news.fobholdings.co.kr

This article is also available in: 한국어 · English · Français · 日本語 · हिन्दी · 简体中文 · العربية